Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.60 and has seen 2.24 million shares traded in the last trading session. The ADAP stock price is -300.0% off its 52-week high price of $1.80 and 0.0% above the 52-week low of $0.45.
The consensus among analysts is that Adaptimmune Therapeutics Plc ADR (ADAP) is Buy stock at the moment, with a recommendation rating of 1.89. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Sporting -0.69% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADAP stock price touched $0.45 or saw a rise of 13.89%. Year-to-date, Adaptimmune Therapeutics Plc ADR shares have moved -17.02%, while the 5-day performance has seen it change -7.64%. Over the past 30 days, the shares of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have changed -27.90%.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 85.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $4.0. In that case, then, we find that the current price level is -788.89% off the targeted high while a plunge would see the stock gain -122.22% from current levels.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
The company’s shares have lost -58.99% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 204.78%.
8 analysts offering their estimates for the company have set an average revenue estimate of 9.01M for the current quarter. 3 have an estimated revenue figure of 6.3M for the next ending quarter. Year-ago sales stood 231k and 5.68M respectively for this quarter and the next, and analysts expect sales will grow by 3,798.81% for the current quarter and 204.78% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.30% over the past 5 years.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
The top two institutional holders are MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares worth more than $38.0 million. As of 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP held 2.5415% of shares outstanding.
The other major institutional holder is BANK OF AMERICA CORP /DE/, with the holding of over 4.65 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.53 million and represent 1.9239% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR Portfolio Developed World ex-US ETF and SEI Institutional International Tr-International Equity . As of Dec 31, 2024 , the former fund manager holds about 0.10% shares in the company for having 251.08 shares of worth $0.11 million while later fund manager owns 246.74 shares of worth $0.11 million as of Dec 31, 2024 , which makes it owner of about 0.10% of company’s outstanding stock.
